Click here to join the case
LOS ANGELES, April 15, 2021 (GLOBE NEWSWIRE) --
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) investors that acquired securities between November 8, 2019, and April 6, 2021.
Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.
It is alleged in this complaint that FibroGen issued misleading and/or false statements and/or failed to disclose information pertinent to investors.On April 6, 2021, FibroGen issued a statement providing “clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (‘CKD’).” FibroGen stated that its safety analysis “included post-hoc changes to the stratification factors.” FibroGen also disclosed, based on analyses using the pre-specified stratification factors, that FibroGen “cannot conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa.” Shares of FibroGen dropped sharply, based on this news.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
